## Abstract Despite improvements in chemotherapy and surgery in the treatment of osteosarcoma (OS), satisfactory results are still difficult to achieve. Novel therapeutic modalities need to be developed for osteosarcoma treatment. The combined effects of tumor necrosis factor‐related apoptosis‐indu
Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells
✍ Scribed by Takeshi Hori; Takashi Kondo; Masahiko Kanamori; Yoshiaki Tabuchi; Ryohei Ogawa; Qing-Li Zhao; Kanwal Ahmed; Taketoshi Yasuda; Shoji Seki; Kayo Suzuki; Tomoatsu Kimura
- Book ID
- 116335288
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 537 KB
- Volume
- 287
- Category
- Article
- ISSN
- 0304-3835
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
While TRAIL is relatively non-toxic to normal cells, it can selectively induce apoptosis in many types of transformed cells. Nevertheless, some non-small cell lung cancer (NSCLC) cells are particularly resistant to the effects of TRAIL. Here, we report that in combination with naringenin exposure to
## Abstract ## BACKGROUND. The tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) death receptor, DR5, mediates proapoptotic signals and is implicated in the pathogenesis of many neoplasms including nonsmall‐cell lung cancer (NSCLC). ## METHODS. In this study, immunohistochemical ex